Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.

Samira Saadoun; Patrick Waters; Gregory P Owens; Jeffrey L Bennett; Angela Vincent; Marios C Papadopoulos

Originally published in Acta neuropathologica communications · 2014-03-31

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Introduction Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are present in some neuromyelitis optica patients who lack antibodies against aquaporin-4 (AQP4-IgG). The effects of neuromyelitis optica MOG-IgG in the central nervous system have not been investigated in vivo. We microinjected MOG-IgG, obtained from patients with neuromyelitis optica, into mouse brains and compared the results with AQP4-IgG. Results MOG-IgG caused myelin changes and altered the expression of axonal proteins that are essential for action potential firing, but did not produce inflammation, axonal loss, neuronal or astrocyte death. These changes were independent of complement and recovered within two weeks. By contrast, AQP4-IgG produced complement-mediated myelin loss, neuronal and astrocyte death with limited recovery at two weeks. Conclusions These differences mirror the better outcomes for MOG-IgG compared with AQP4-IgG patients and raise the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.

Discussion

Although there is growing interest in the potential pathogenicity of MOG antibodies in NMO, the effects of NMO MOG-IgG have not been explored in vivo. Our results indicate that MOG-IgG directly damages myelin. The detrimental effects of MOG-IgG markedly differ from those of AQP4-IgG and are reversible (see Table 1).

Conclusions

MOG-IgG obtained from neuromyelitis optica patients causes myelin changes and alters the expression of axonal proteins when injected in mouse brain. These effects are not associated with inflammatory cell infiltration, are largely independent of complement and recover within two weeks. AQP4-IgG obtained from neuromyelitis optica patients causes complement-mediated myelin loss, inflammatory cell infiltration, neuronal and astrocyte death with limited recovery at two weeks. These findings raise the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?